Windlas Biotech Ltd

Stage 2 · Advancing · week 13Setup 6.2 ★ FairStrong +7.3

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. More about the company

₹1,022
-1.37% today
₹2,109 Cr · Small cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-11.5%
₹705.8 lo₹1,154.8 hi
11.5% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 13
1w13w26w
Week 13 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
19.1%
200 DMA: ₹858.1 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.45x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +1.2% vs MA50 +10.5%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-9.3%
3M
+23.5%
6M
+32.5%
YTD
+26.2%
1Y
+12.6%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
This stock ranks #50 of 77 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Ranks #42 of 61 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-12 → 2026-10-07
S2 16w
S2 61w
2023-07-122026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 16w → S3 2w → S2 61w → S3 11w → S4 2w → S1 2w → S2 6w → S3 1w → S4 7w → S1 4w → S2 5w → S3 4w → S4 13w → S1 3w → S4 7w → S1 10w → S2 12w current
Total tracked: 168 weeks across 17 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-07
Pullback Hunter
Latest: 2026-08-21
60 appearances in last 60 days. First seen: 2026-07-24.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S2
Wk 13 · Vol 0.45x
2026-10-06S2
Wk 12 · Vol 0.41x
2026-10-05S2
Wk 12 · Vol 0.63x
2026-10-01S2
Wk 12 · Vol 0.37x
2026-09-30S2
Wk 12 · Vol 0.33x
2026-09-29S2
Wk 12 · Vol 0.64x
2026-09-28S2
Wk 11 · Vol 0.69x
2026-09-25S2
Wk 11 · Vol 0.25x
2026-09-24S2
Wk 11 · Vol 0.31x
2026-09-23S2
Wk 11 · Vol 0.56x
2026-09-22S2
Wk 11 · Vol 0.30x
2026-09-21S2
Wk 10 · Vol 0.76x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹1,010
200 DMA
₹858.1
52W High
₹1,154.8
52W Low
₹705.8
5D Low
₹1,017.9
Resistance levels (recent highs)
20d High
₹1,146.1
60d High
₹1,154.8
120d High
₹1,154.8
250d High
₹1,154.8
Next resistance
+12.1%
to 20d High
Ask the Market AI about WINDLASAsk →
P/E (TTM)
26.3
Forward —
Earnings Growth (YoY)
-2.6%
Revenue +17.7%
ROE
+12.2%
Profit margin +7.4%
Dividend Yield
0.70%
P/B 3.2
About this companyHealth Care· Pharmaceuticals

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.